v3.26.3
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS (Tables)
 9 Months Ended
Sep. 30, 2026
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS  
Schedule of condensed consolidating balance sheet

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

$-

 

 

$360

 

 

$76,499

 

 

$-

 

 

$502,493

 

 

$-

 

 

$579,352

 

Investment in subsidiaries and variable interest entity (VIE)

 

 

(2,181,987)

 

 

930,000

 

 

 

-

 

 

 

-

 

 

 

547,876

 

 

 

704,111

 

 

 

-

 

Intercompany receivables

 

 

-

 

 

 

-

 

 

 

464,474

 

 

 

-

 

 

 

954,508

 

 

 

(1,418,982)

 

 

-

 

Other assets

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

72,040

 

 

 

(1)

 

 

72,039

 

Total Assets

 

$(2,181,987)

 

$930,360

 

 

 

540,973

 

 

 

-

 

 

 

2,076,917

 

 

 

(714,872)

 

 

651,391

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

$-

 

 

$150,000

 

 

$54,309

 

 

$-

 

 

$3,345,118

 

 

$-

 

 

$3,549,427

 

Intercompany payables

 

 

-

 

 

 

-

 

 

 

46,770

 

 

 

-

 

 

 

1,372,213

 

 

 

(1,418,983)

 

 

-

 

Other liabilities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Total Liabilities

 

 

-

 

 

 

150,000

 

 

 

101,079

 

 

 

-

 

 

 

4,717,331

 

 

 

(1,418,983)

 

 

3,549,427

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' Deficit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital stock and additional paid in capital

 

 

-

 

 

 

1,569,229

 

 

 

888,731

 

 

 

-

 

 

 

4,852,163

 

 

 

(1,670,820)

 

 

5,639,303

 

Accumulated deficit

 

 

(2,181,987)

 

 

(788,869)

 

 

(448,837)

 

 

-

 

 

 

(7,404,231)

 

 

2,374,931

 

 

 

(8,448,993)

Accumulated other comprehensive income (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(40,260)

 

 

-

 

 

 

(40,260)

Non—controlling interests

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(48,086)

 

 

-

 

 

 

(48,086)

Total Deficit

 

 

(2,181,987)

 

 

780,360

 

 

 

439,894

 

 

 

-

 

 

 

(2,640,414)

 

 

704,111

 

 

 

(2,898,036)

Total Liabilities and Shareholders' Equity

 

$(2,181,987)

 

$930,360

 

 

$540,973

 

 

$-

 

 

$2,076,917

 

 

$(714,872)

 

$651,391

 
Schedule of condensed consolidating statement of operations

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of product and services

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Cost of goods and services sold

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Gross profit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Total operating expenses

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

731,522

 

 

 

-

 

 

 

731,522

 

Loss from operations

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(731,522 )

 

 

-

 

 

 

(731,522 )

Other income (expense)

 

 

-

 

 

 

-

 

 

 

1

 

 

 

-

 

 

 

(35,952 )

 

 

-

 

 

 

(35,951 )

Equity in net loss of subsidiaries and variable interest entity (VIE)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net Loss

 

$-

 

 

$-

 

 

$1

 

 

$-

 

 

$(767,474 )

 

$-

 

 

$(767,473 )